• Something wrong with this record ?

EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells

N. Schumacher, I. Thomsen, F. Brundert, V. Hejret, S. Düsterhöft, B. Tichý, D. Schmidt-Arras, M. Voss, S. Rose-John

. 2023 ; 1870 (7) : 119489. [pub] 20230602

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23016160

The cytokine interleukin-6 (IL-6) has considerable pro-inflammatory properties and is a driver of many physiological and pathophysiological processes. Cellular responses to IL-6 are mediated by membrane-bound or soluble forms of the IL-6 receptor (IL-6R) complexed with the signal-transducing subunit gp130. While expression of the membrane-bound IL-6R is restricted to selected cell types, soluble IL-6R (sIL-6R) enables gp130 engagement on all cells, a process termed IL-6 trans-signalling and considered to be pro-inflammatory. sIL-6R is predominantly generated through proteolytic processing by the metalloproteinase ADAM17. ADAM17 also liberates ligands of the epidermal growth factor receptor (EGFR), which is a prerequisite for EGFR activation and results in stimulation of proliferative signals. Hyperactivation of EGFR mostly due to activating mutations drives cancer development. Here, we reveal an important link between overshooting EGFR signalling and the IL-6 trans-signalling pathway. In epithelial cells, EGFR activity induces not only IL-6 expression but also the proteolytic release of sIL-6R from the cell membrane by increasing ADAM17 surface activity. We find that this derives from the transcriptional upregulation of iRhom2, a crucial regulator of ADAM17 trafficking and activation, upon EGFR engagement, which results in increased surface localization of ADAM17. Also, phosphorylation of the EGFR-downstream mediator ERK mediates ADAM17 activity via interaction with iRhom2. In sum, our study reveals an unforeseen interplay between EGFR activation and IL-6 trans-signalling, which has been shown to be fundamental in inflammation and cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016160
003      
CZ-PrNML
005      
20240103104037.0
007      
ta
008      
231013s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbamcr.2023.119489 $2 doi
035    __
$a (PubMed)37271223
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Schumacher, Neele $u Institute of Biochemistry, Medical Faculty, Kiel University, Germany. Electronic address: nschumacher@biochem.uni-kiel.de
245    10
$a EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells / $c N. Schumacher, I. Thomsen, F. Brundert, V. Hejret, S. Düsterhöft, B. Tichý, D. Schmidt-Arras, M. Voss, S. Rose-John
520    9_
$a The cytokine interleukin-6 (IL-6) has considerable pro-inflammatory properties and is a driver of many physiological and pathophysiological processes. Cellular responses to IL-6 are mediated by membrane-bound or soluble forms of the IL-6 receptor (IL-6R) complexed with the signal-transducing subunit gp130. While expression of the membrane-bound IL-6R is restricted to selected cell types, soluble IL-6R (sIL-6R) enables gp130 engagement on all cells, a process termed IL-6 trans-signalling and considered to be pro-inflammatory. sIL-6R is predominantly generated through proteolytic processing by the metalloproteinase ADAM17. ADAM17 also liberates ligands of the epidermal growth factor receptor (EGFR), which is a prerequisite for EGFR activation and results in stimulation of proliferative signals. Hyperactivation of EGFR mostly due to activating mutations drives cancer development. Here, we reveal an important link between overshooting EGFR signalling and the IL-6 trans-signalling pathway. In epithelial cells, EGFR activity induces not only IL-6 expression but also the proteolytic release of sIL-6R from the cell membrane by increasing ADAM17 surface activity. We find that this derives from the transcriptional upregulation of iRhom2, a crucial regulator of ADAM17 trafficking and activation, upon EGFR engagement, which results in increased surface localization of ADAM17. Also, phosphorylation of the EGFR-downstream mediator ERK mediates ADAM17 activity via interaction with iRhom2. In sum, our study reveals an unforeseen interplay between EGFR activation and IL-6 trans-signalling, which has been shown to be fundamental in inflammation and cancer.
650    12
$a protein ADAM17 $7 D000072198
650    _2
$a cytokinový receptor gp130 $x genetika $7 D050822
650    _2
$a epitelové buňky $x metabolismus $7 D004847
650    _2
$a erbB receptory $x genetika $x metabolismus $7 D066246
650    12
$a interleukin-6 $x genetika $x metabolismus $7 D015850
650    12
$a signální transdukce $x genetika $7 D015398
650    _2
$a lidé $7 D006801
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Thomsen, Ilka $u Institute of Biochemistry, Medical Faculty, Kiel University, Germany
700    1_
$a Brundert, Florian $u Institute of Biochemistry, Medical Faculty, Kiel University, Germany
700    1_
$a Hejret, Vaclav $u CEITEC-Central European Institute of Technology, Masaryk University, Czech Republic
700    1_
$a Düsterhöft, Stefan $u Institute of Molecular Pharmacology, University Hospital Aachen/RWTH, Aachen, Germany
700    1_
$a Tichý, Boris $u CEITEC-Central European Institute of Technology, Masaryk University, Czech Republic $7 xx0312236
700    1_
$a Schmidt-Arras, Dirk $u Institute of Biochemistry, Medical Faculty, Kiel University, Germany
700    1_
$a Voss, Matthias $u Institute of Biochemistry, Medical Faculty, Kiel University, Germany
700    1_
$a Rose-John, Stefan $u Institute of Biochemistry, Medical Faculty, Kiel University, Germany
773    0_
$w MED00000719 $t Biochimica et biophysica acta. Molecular cell research $x 1879-2596 $g Roč. 1870, č. 7 (2023), s. 119489
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37271223 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20240103104033 $b ABA008
999    __
$a ok $b bmc $g 1999968 $s 1202522
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 1870 $c 7 $d 119489 $e 20230602 $i 1879-2596 $m Biochimica et biophysica acta. Molecular cell research $n Biochem Biophys Acta $x MED00000719
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options